Re: Kerrington Powell, Michael C. Burns, Vinay Prasad. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint. Eur Urol. 2023;83:101-2

Eur Urol. 2023 May;83(5):e136. doi: 10.1016/j.eururo.2023.01.025. Epub 2023 Feb 9.

Authors

Francesco Montorsi¹, Simone Scuderi², Alberto Briganti¹, Giorgio Gandaglia¹

Affiliations

¹ Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, 20132 Milan, Italy.
² Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, 20132 Milan, Italy. Electronic address: [email protected].

PMID: 36774225
DOI: 10.1016/j.eururo.2023.01.025

No abstract available

Publication types

Letter
Comment

MeSH terms

Burns*
Humans
Phenylurea Compounds*
Pyrimidinones
United States
United States Food and Drug Administration

Substances

relugolix
Phenylurea Compounds
Pyrimidinones